|Articles|July 1, 2004

Where there's smoke, there's financial incentive to put out the fire

For health plans to implement a tobacco-reduction intervention, the cost is about 22 cents PMPY.

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Subscribe

Related Content

Adverse drug events after hospitalization: 'These are the sickest people that we have who are not in the hospital'

ByPeter Wehrwein, Managing Editor

March 21st 2026

female pharmacist on right looking at computer screen on right | ©Maksym stock.adobe.com

Putting pharmacists in charge of medication management as patients leave the hospital seems like a good idea. Does it work?

ByPeter Wehrwein, Managing Editor

March 19th 2026

The Great Healthcare Plan, MFN drug prices and the political implications of the end of ACA enhanced subsidies: Here are 7 takeaways from the MHE-AJMC webinar

ByPeter Wehrwein, Managing Editor

Published: March 4th 2026 | Updated: April 8th 2026

tariff spelled out with blocks with letters American flag in the background | ©Andrii

8 things you need to understand about tariffs on pharmaceuticals and other healthcare products after last week’s Supreme Court ruling

ByPeter Wehrwein, Managing Editor

February 23rd 2026

7 things you need to know about the PBM reforms signed into law this week

ByDenise Myshko,Peter Wehrwein, Managing Editor

February 6th 2026

Latest CME

Virtual Event

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

August 24, 2026

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

In-Person + Virtual Event

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

September 12, 2026

Multimedia

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

Video

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

Video

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Video

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Video

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

Video

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Video

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Video

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Video

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Where there's smoke, there's financial incentive to put out the fire

Related Content

Adverse drug events after hospitalization: 'These are the sickest people that we have who are not in the hospital'

Putting pharmacists in charge of medication management as patients leave the hospital seems like a good idea. Does it work?

The Great Healthcare Plan, MFN drug prices and the political implications of the end of ACA enhanced subsidies: Here are 7 takeaways from the MHE-AJMC webinar

8 things you need to understand about tariffs on pharmaceuticals and other healthcare products after last week’s Supreme Court ruling

7 things you need to know about the PBM reforms signed into law this week

Latest CME

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

27th Annual International Lung Cancer Congress®

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

26th Annual International Lung Cancer Congress

20th Annual New York Lung Cancers Symposium®

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Trending on Managed Healthcare Executive

Overlooked bladder nerves now thought to reduce UTI burden through pain signaling, study shows

Real-World Usage of Biologics in Psoriatic Arthritis

Medicare beneficiaries are paying more for price-negotiated drugs, survey finds

Researchers discover new pathway to fight liver inflammation

FDA approves $2.7 million gene therapy for rare metabolic disorder